Table 1.
Baseline characteristics of patients and treatments with newly diagnosed brain metastases.
| Patient characteristic | |
|---|---|
| Gender – no. (%) | |
| Male | 127 (57) |
| Female | 167 (43) |
| Age – years (IQR) | 63 (55–70) |
| Total intracranial tumor volume – mm3 (IQR) | 1.7 (0.7–3.7) |
| Primary diagnosis – no. (%) | |
| NSCLC | 152 (52) |
| Breast cancer – all types | 63 (22) |
| Melanoma | 64 (22) |
| Renal cell carcinoma | 15 (5) |
| ECOG – no. (%) | |
| 0 | 93 (32) |
| 1 | 151 (51) |
| 2 | 39 (13) |
| 3+ | 11 (4) |
| Extracranial metastatic burden – no. sites (%) | |
| 0 | 63 (21) |
| 1 | 124 (42) |
| 2 | 52 (18) |
| 3 | 27 (9) |
| 4 | 21 (7) |
| 5+ | 7 (2) |
| Systemic disease status – no. (%) | |
| Controlled | 96 (33) |
| Uncontrolled | 198 (67) |
| Number of metastases – median no. (IQR) | 2 (1–4) |
| Whole brain radiation therapy – no. (%)a | 52 (23) |
| Cranial surgery – no. (%)a | 62 (21) |
| Isodose % (IQR) | 50 (50–80) |
| Isocenters – median (IQR) | 3 (1–6) |
| Dose – median (IQR) | 19 (18–20) |
| Fractions – no. (%) | |
| 1 | 267 (91) |
| 2 | 25 (8) |
| 3 | 2 (1) |
aTreatment received after SRS.